EMEA-002081-PIP01-16 - paediatric investigation plan

Ramipril

Indapamide

Key facts

• Active Substance:
  • Ramipril
  • Indapamide
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0125/2017
• PIP number:
  EMEA-002081-PIP01-16
• Pharmaceutical form(s):
  Modified-release tablet
• Condition(s) / indication(s):
  Treatment of hypertension
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  05/05/2017

Decision

P/0125/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-002081-PIP01-16)

AdoptedReference Number: EMA/253504/2017